www.siu-urology.org #B2BGUCancerTriad

December 13–14, 2019 in Berlin, Germany

Register now!

SCIENTIFIC PROGRAMME COMMITTEE

Peter BLACKCanada

Peter HAMMERERGermany

Pilar LAGUNATurkey

Rafael SANCHEZ-SALASFrance

TIME SESSION TITLE INVITED SPEAKERS

0800 Welcome and Introduction Peter Black, Canada and Pilar Laguna, Turkey

Clinical Development of Immunotherapy for Bladder Cancer

0815–0835 Immunotherapy in Metastatic Urothelial Carcinoma Petros Grivas, United States

Where to next?

0835–0850 Perioperative Immunotherapy for MIBC Andrea Necchi, Italy

0850–0905 Combining Trimodal Therapy with Checkpoint Blockade Wassim Kassouf, Canada

0905–0920 Immunotherapy and Evolving Therapies in NMIBC Peter Black

0920–0945 Discussion / Q&A

Moderator: Peter BlackPetros Grivas, United StatesWassim Kassouf, CanadaAndrea Necchi, Italy

0945–1010 Health Break

Clinical Development of Immunotherapy for Kidney Cancer

1010–1030 Immunotherapy in Metastatic RCC Christian Kollmannsberger, Canada

1030–1115 Multimodal Therapy of mRCC: Case-based Panel (to include discussion of cytoreductive Nx and SABR or surgery of mets)

Moderator: Michael Staehler, Germany Axel Bex, The NetherlandsDirk Böhmer, GermanyChristian Kollmannsberger, Canada

1115–1135 Role of Perioperative IO and Targeted Therapy in High-risk RCC Viktor Grünwald, Germany

Adverse Events/Toxicities

1135–1220 Case-based Discussions on Adverse Events / Toxicities Associated with Immunotherapy

Moderator: Kilian Gust, AustriaChristian Kollmannsberger, CanadaPablo Maroto Rey, SpainAndrea Necchi, ItalySrikala Sridhar, Canada

1220–1320 Lunch Break

Biomarkers of Response to Therapy

1320–1405 Developing Biomarkers for Clinical Utilization in Advanced Bladder Cancer: Panel Discussion

Moderator: Andrea Necchi, Italy Petros Grivas, United StatesGopa Iyer, United StatesTilman Todenhöfer, Germany

1405–1435 The Microbiome in Tumor Immunology Lisa Derosa, France

1435–1450 Health Break

The Pipeline

1450–1510 FGFR Inhibitors in Urothelial Carcinoma Gopa Iyer, United States

1510–1530 Antibody Drug Conjugates in Urothelial Carcinoma Srikala Sridhar, Canada

1530–1550 State of the Art: CAR-T-Cell Therapy

1550–1610 DiscussionModerators: Peter Black and Pilar Laguna Gopa Iyer, United StatesSrikala Sridhar, Canada

1610–1630 Concluding Remarks Peter Black and Pilar Laguna

Day 1Friday, December 13, 2019

Day 2Saturday, December 14, 2019

TIME SESSION TITLE INVITED SPEAKERS

Part I. Prostate Cancer I

0800–0810 Welcome Message Peter Hammerer, Germany and Rafael Sanchez-Salas, France

0810–0830 Who and When: Germ-line DNA Testing in Prostate Cancer Patients Thorsten Schlomm, Germany

Management of High Risk Non-metastatic Prostate Cancer

0830–0845 What is important for the surgeon? Rafael Sanchez-Salas

0845–0905 What is important for the radiotherapist? Alberto Bossi, France

0905–0925 Discussion (with Q&A)

Moderator: Peter HammererAlberto Bossi, FranceRafael Sanchez-SalasThorsten Schlomm, Germany

Managing Oligometastatic Prostate Cancer

0925–0945 Treatment of the Primary Prasanna Sooriakumaran, United Kingdom

0945–1005 Definitive Treatment of the Mets Dirk Böhmer, Germany

1005–1025 Systemic Therapy Noel Clarke, United Kingdom

1025–1110 Case-based Panel Discussion (with Q&A)

Moderator: Rafael Sanchez-SalasDirk Böhmer, GermanyKarim Fizazi, FrancePeter Hammerer, GermanyNoel Clarke, United KingdomPrasanna Sooriakumaran, United Kingdom

1110–1130 Health Break

Part II. Prostate Cancer II

1130–1155 Managing Biochemical Recurrence after Definitive Local Therapy: Case-based Panel Discussion (with Q&A)

Moderator: Peter Hammerer Alberto Bossi, FranceAxel Heidenreich, GermanyPablo Maroto Rey, SpainDerya Tilki, GermanyRafael Sanchez-Salas, France

1155–1215 Sequencing of Systemic Therapy for mCSPC & mCRPC Karim Fizazi, France

1215–1235 Liquid Biopsy to Support Clinical Decision-making Klaus Pantel, Germany

1235–1255 nmCRPC: Treatment Options in an Endangered Disease State Antonio Alcaraz, Spain

1255–1345 Lunch Break

mCRPC Systemic Therapy Pipeline

1345–1405 Immunotherapy Pablo Maroto Rey, Spain

1405–1425 PARP Inhibitors Noel Clarke, United Kingdom

1425–1445 PSMA-Theranostics Frederik Giesel, Germany

1445–1500 Concluding Remarks Peter Hammerer and Rafael Sanchez-Salas

Registration Rates

Urologists Medical Oncologists Radiation Oncologists Other Specialists

€150ResidentsTraineesFellowsNurses

€65

Meeting VenueBerlin Marriott HotelInge-Beisheim-Platz 110785 Berlin, Germany

This programme is made possible by unrestricted educational grants provided by Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd and Ferring Pharmaceuticals.